DC-PEACETECH-LAB
24.12.2021 11:02:08 CET | Business Wire | Press release
The International Peace Honors (IPH), created by PeaceTech Lab , an award-winning non-profit organization founded by the United States Institute of Peace , will recognize Forest Whitaker, Ajay Banga, Juanes, Tokata Iron Eyes, Brandon Stanton, Dr. Lisa Su and Nicholas Donofrio for being global change-makers who have positively impacted the world through targeted activism. The virtual event airs Sunday, February 27th, 2022, at 8:00 pm EST. To register to watch visit: internationalpeacehonors.org .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211223005439/en/
“This year’s International Peace Honorees inspire us to greater hope and urgency, by showing what can happen when we leverage technology and media in their highest forms. From promoting peace and non-violence through music, to helping people improve their lives through the digital economy, protect the planet, and raise up a generation of new voices, their tireless work for the betterment of humanity is to be lauded. We are thrilled to recognize each of these outstanding social leaders,” said Sheldon Himelfarb , President & CEO, PeaceTech Lab.
Academy Award Winner, Forest Whitaker will receive the recognition for his everlasting commitment to empowering youth and promoting peace globally. Whitaker is the CEO/Founder of the Whitaker Peace & Development Initiative (WPDI), which provides educational tools and economic opportunities to young people in places touched by exclusion, violence and armed conflict.
Mastercard Executive Chairman, Ajay Banga will receive the honor for his outstanding contributions in bringing the digital economy to over 1 billion people, thus creating a sustainable economy through technology.
Renowned Singer-Songwriter and Social Advocate, Juanes will be honored for his dedication to youth empowerment and peace in his native Colombia through his Mi Sangre Foundation , a peace-building non-profit organization he co-founded alongside Catalina Cock Duque.
Youth Activist, Tokata Iron Eyes is set to be honored for her impassioned advocacy for Indigenous rights and the global climate movement. At age 18, she becomes the youngest person to receive the prestigious award.
Brandon Stanton , the creator of “Humans of New York” , will be celebrated for his dedication to fostering empathy and interconnectedness through powerful storytelling.
AMD ’s President and CEO, Dr. Lisa Su , will be recognized for revolutionizing high performance computing, donating supercomputing power for public good efforts focused on infectious disease research, and for inspiring people from all backgrounds to pursue careers in science and technology.
Lastly, former IBM EVP of Innovation and Technology Nicholas Donofrio , will receive the honor for his contributions to the international community of women and underrepresented youth in the fields of education, engineering, business and mathematics.
“The exceptionalism of our honorees reminds us that we’re all capable of rising to the challenges that negatively affect our world. I’m proud to extol their valuable social contributions and celebrate their vast achievements,” added MariaEsmeralda Paguaga , executive producer of the International Peace Honors .
The host, performers, and special guests will be announced in the upcoming weeks.
The International Peace Honors are made possible with the generosity of its sponsors and donors: Mastercard, BNY Mellon, The MITRE Corporation, Microsoft, Pitney Bowes, Liberty Mutual Insurance, Ernst & Young, Mercator XXI, KUDO, Wipro, and Alliance for Peacebuilding.
Follow @internationalpeacehonors for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005439/en/
Link:
Social Media:
https://www.facebook.com/peacetechlab/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom